John Weinberg, MD, COO, Veloxis Pharmaceuticals, describes the benefits of the Veloxis’ Envarsus, an orphan drug for the treatment of organ transplant rejection. Envarsus is a reformulation of tacrolimus,…
John Weinberg, MD, COO, Veloxis Pharmaceuticals describes the challenges of organ transplantation. While advancements in the field have minimized the short-term risks of transplantation, the average kidney transplant only lasts…
John Weinberg, MD, COO, Veloxis Pharmaceuticals, talks about the challenges in current organ transplantation methods, and Veloxis’ once-daily solution to advancing kidney transplantation. According to Weinberg, most kidney transplants…
By Will Boggs, MD NEW YORK (Reuters Health) – Temsirolimus does not improve progression-free survival in metastatic renal cell carcinoma (RCC) compared to standard treatment, according to results…
Researchers at a university in eastern Zhejiang Province have used a 3D printer to create living kidneys, which are expected to be used for transplants in the future.
NEW YORK (Reuters Health) – Impaired kidney function related to treatment of childhood cancer does not recover over time, according to a Dutch study reported in Cancer Epidemiology,…
NEW YORK (Reuters Health) – A novel VEGFR inhibitor, tivozanib, improves progression-free survival significantly in patients with metastatic renal cell carcinoma but does not improve overall survival, according…
By Genevra Pittman NEW YORK (Reuters Health) – Men treated for prostate cancer with androgen deprivation therapy have a higher risk of developing kidney problems, a new study…
